

## Special Issue

# Gynecological Oncology: Pathogenesis, Immune Surveillance and Therapeutic Opportunities

### Message from the Guest Editor

This Special Issue aims to gather research papers that delve into pathogenetic pathways, the intricate interplay of the immune system, and innovative approaches to cancer therapy within gynecologic oncology. The Cancer Genome Atlas initiative has deeply contributed to the body of knowledge regarding the molecular aspects of gynecological neoplasms, particularly in endometrial cancer. Moreover, encouraging advances have been seen in immunotherapy for endometrial cancer. The discovery of new potential targets like the folate receptor offers new hopes in the treatment of platinum-resistant ovarian cancer, where the benefit from current treatment options is highly limited. Despite progress in cervical cancer due to screening strategies and vaccines, challenges persist, including ensuring broader access to primary prevention and improving outcomes for patients with recurrent and advanced disease. We warmly invite experts in the field to contribute their insights, particularly those focusing on elucidating the fundamental mechanisms of pathogenesis, identifying novel therapeutic targets, and unraveling the intricate role of the immune system in gynecologic oncology.

---

### Guest Editor

Dr. Martino Rolla

Department of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, Italy

---

### Deadline for manuscript submissions

closed (25 November 2024)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/201699](https://mdpi.com/si/201699)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).